Haven: The strategy that didn’t fix healthcareJohn Singer discusses the disbanding of Haven, the joint healthcare venture by Amazon, JP Morgan and Berkshire Hathaway, Share XHaven: The strategy that didn’t fix healthcarehttps://pharmaphorum.com/views-analysis-market-access/haven-strategy-healthcare/
Ireland is open: The biologics boom boosting the Irish economyThe life sciences industry has an important role in the Irish economy, with sectors such as biologics booming Share XIreland is open: The biologics boom boosting the Irish economyhttps://pharmaphorum.com/views-analysis-market-access/ireland-is-open-the-biologics-boom-boosting-the-irish-economy/
Stay calm and carry on: How to implement the updated ABPI codeDon’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to Share XStay calm and carry on: How to implement the updated ABPI codehttps://pharmaphorum.com/views-analysis-market-access/how-to-implement-the-updated-abpi-code/
VPAS: Progress two years in and opportunities to improve over next three yearsIn the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Progress two years in and opportunities to improve over next three yearshttps://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/
VPAS: Achievement so far on objectives for the economy and innovationIn the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Share XVPAS: Achievement so far on objectives for the economy and innovationhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-the-economy-and-innovation/
VPAS: Achievements so far on affordabilityIn the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing Share XVPAS: Achievements so far on affordabilityhttps://pharmaphorum.com/views-analysis-market-access/vpas-achievements-so-far-on-affordability/
VPAS: Achievement so far on objectives for patientsThe UK has a voluntary agreement that was struck by the government and NHS England (now referred to Share XVPAS: Achievement so far on objectives for patientshttps://pharmaphorum.com/views-analysis-market-access/vpas-achievement-so-far-on-objectives-for-patients/
Assessing the impact of prevalence on pricing of rare disease drugs in GermanyIn this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss Share XAssessing the impact of prevalence on pricing of rare disease drugs in Germanyhttps://pharmaphorum.com/views-analysis-market-access/assessing-pricing-of-rare-disease-drugs-in-germany/
2021 market access prospects for ItalyItaly was working up big changes in market access throughout 2020 which will be implemented in 2021. In Share X2021 market access prospects for Italyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-italy/
